On August 4, 2026, the Milken Institute published its Coverage and Reimbursement Roadmap for Women's Health Innovation, a report that got broader industry pickup on August 25 via Femtech Insider. Produced by the Milken Institute Women's Health Network's Coverage and Reimbursement Working Group and authored by Abigail Humphreys, Jenica Patterson, Esther Krofah, and Lee Fleisher, the roadmap makes an argument the sector has been muttering for years and finally puts structure on it: promising women's health innovations "stall not for lack of science but for lack of a clear path to payment."

Why It Matters

This is the missing manual for the femtech and sexual health hardware boom, and its timing is not accidental — it lands the same month Channel Medsystems raised $30 million explicitly for commercialization and provider training rather than R&D, and weeks after a record run of women's health funding. The graveyard of cleared-but-uncovered femtech devices is real: pelvic floor trainers, menopause devices, and fertility hardware that hold FDA clearances and no reimbursement, sold direct-to-consumer at $200-$400 because self-pay was the only pathway left after the payer route failed. For investors, the nine barriers are a diligence checklist. For founders in sexual and reproductive health, the practical takeaway is that "self-pay" is a legitimate strategic choice with its own playbook — but only if you choose it deliberately, price for it, and stop pretending an insurance line is coming later.

The report identifies nine structural barriers standing between women's health innovations and reimbursement. As summarized by Femtech Insider, they include the undervaluation of women's health, fragmented payer pathways, limited billing and reimbursement mechanisms, gaps in sex-specific evidence, reimbursement uncertainty, administrative complexity, prior authorization, and limited clinician adoption. Milken frames the underlying cause bluntly: women's health has "long been underserved by a coverage system built around inadequate research, insufficient billing codes, and payers that have been slow to recognize conditions that affect women exclusively, differentially, or disproportionately."

The more actionable half of the document is its comparison of three go-to-market coverage pathways — self-pay, commercial payer coverage, and public programs including Medicaid's state-by-state variation and Medicare's four distinct parts — with step-by-step guidance and optimal timing for each. The working group's central operational advice is that the choice between self-pay and payer coverage should be made early, not retrofitted after clearance, and that founders should engage payers and clinicians before evidence generation is complete so trial design actually produces what coverage decisions require. The report was assembled from a workshop convening clinicians, payers, regulators, and innovators.

For a sector that has spent a decade optimizing for FDA clearance as the finish line, this is a fairly pointed correction. Clearance establishes that a device is safe and effective. It says nothing about whether a CPT code exists, whether a commercial plan will cover it, whether a prior authorization workflow will bury it, or whether an OB/GYN will change a familiar protocol to adopt it. Those four questions determine revenue, and the roadmap argues they should be answered on day one rather than year five.

Sources

Update — 2026-08-26

{Initial entry — story first created.}